Best Dermatology Companies in South Korea
The 73 best Dermatology companies in South Korea in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: ExocoBio.
- Dermatology Market Size Worth USD 2.04 Billion in 2030
Ranked: Best Dermatology companies in South Korea
| # | Company | Disclosed funding | Last round | Stage | Founder | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ExocoBio Developer of exosome-based therapeutics for regenerative medicine | $47M | 69 mo ago | Series C | Byong Cho Co-Founder & CEO | 2017 | PHPNginx | 203 patents Exosome-derived bioactive ingredients for anti‑inflammatory, wound‑healing and cosmetic applications | — |
| 2 | Shaperon Developer of therapies for multiple diseases 24Patents top 20%Innovation top 24%Funding top 29%Moat top 35% All 10 signals ▾Patentstop 20% Innovationtop 24% Fundingtop 29% Moattop 35% Newstop 39% Talentbottom 49% Globalbottom 40% Marketbottom 30% Fin. healthbottom 18% Techbottom 16% Patents: 116 patents matched (strict assignee match) · 105 filings since 2022 vs 9 in 2017-21 Innovation: 116 patents (top 24% of patent-holders) · 105 filings since 2022 vs 9 in 2017-21 rank vs industry peers · Fliar Intelligence Index 24/100 | $23M | 2 mo ago | Public | Seung Seong Founder & CEO | 2008 | PHPUNIXOpenSSL+7 | 116 patents Patents concentrated in health & consumer products | — |
| 3 | PharmaResearch Products Developer of cell and tissue regeneration technology | $22M | 99 mo ago | Public | — | 1993 | — | — | — |
| 4 | Neomics Protein therapeutics for dermatological disorders | $1M | 212 mo ago | Seed | Sunghoon Kim Founder | 2005 | — | 21 patents Cosmetic skin-lightening peptides, aniline-based whitening agents, and gene‑therapy vectors. | — |
| 5 | HaplnScience Developer of drugs for anti-ageing and osteoarthritis treatment | — | 83 mo ago | Series A | Hak Choi CEO | 2018 | — | 94 patents Patents concentrated in health & consumer products | — |
| 6 | Anterogen Adipose-derived stem cells for therapeutic applications | — | 89 mo ago | Public | — | 2000 | PHPCentOSApache HTTP Server | 110 patents MSC‑hydrogel scaffolds for skin regeneration/wound healing and antiviral prodrug therapies | — |
| 7 | Bioceltran Using Protein transduction (PTD) technology to develop cosmetics and dermatological pharma products | — | 140 mo ago | Series A | — | 2008 | — | 34 patents Patents concentrated in health & consumer products | — |
| 8 | Across Hyaluronic acid gel product for reducing facial wrinkles | — | — | Funding Raised | Ha Woo Seong CEO | 2009 | Naver AnalyticsOpen Graph | 9 patents Biocompatible biomaterials for tissue repair and dental bone regeneration | — |
Top 7 Dermatology companies in South Korea
#1
Public · Seoul, Seoul · founded 2008 · 48 employees$23.2Mraised▾
Shaperon is the developer of therapies for multiple diseases. The platform is mainly focusing on inflammatory diseases, dermatitis, nonotherapy for cancer and developing multi-targeting stable protein structure. The platform also has multiple pipeline products include Nugel for atopic dermatitis indication are in phase two clinical trials, Nusepin for sepsis indication is in phase one clinical trials, and NuCerin for Alzheimer's indication is in preclinical stage among others.
- Apr 2026Post IPO$5.8M
- Nov 2025Post IPO$17.4M
#2
Series C · Seoul, Seoul · founded 2017 · 99 employees$47.3Mraised▾
ExocoBio has developed an exosome-based therapeutics for regenerative medicine. The therapy uses exosomes secreted by stem cells which stimulate cellular regeneration. The stem cell-derived exosomes contain growth factors and are involved in cell-to-cell communication. The ASC-Exosome has been developed for skin regeneration. The company is developing exosome-based cosmeceuticals, medical devices, skin & hair regeneration and biopharmaceuticals.
- Aug 2020Series C$9.3M
- Sep 2018Series B$27M
- May 2017Series A$11M
#3
Public · Gangneung si, Gangwon Province · founded 1993 · 305 employees$22.4Mraised▾
Pharma Research is a developer of cell and tissue regeneration technology. The company has developed their products including REJURAN and D+CELL 350 TRA which can cure wrinkles, repair skin wound, relieve climacteric, and others. In addition, they also provide health care products which help to improve body immune systems, liver functions, relieve fatigue. Other products include vitamins and medical equipment for personal care. The company has also developed polydeoxyribonucleotide based therapeutics for wound treatment.
- Mar 2018Post IPO$22.4M
#4
Seed · Seoul, Seoul · founded 2005$1Mraised▾
Neomics develops targeted protein therapeutics for dermatological disorders. It is focused on a protein Neo-prep, that is derived from AIMP1(aminoacyl tRNA synthetase interacting multifunctional protein 1, p43) . The company is developing a companion diagnostic as well, and is exploring indications in aging and other skin disorders. In addition, it also provides both products and services for life science research.
- Oct 2008Seed$1M
#5
Series A · Seongnam-si, Gyeonggi-do · founded 2018 · 16 employees—raised▾
HaplnScience developer of drugs for anti-aging and osteoarthritis treatment. The company pipeline drug candidates are HS101, targeting musculoskeletal, for osteoarthritis, is in the pre-clinical stage, HS201 and HS301 targeting skin and hair health for treating wrinkles and aged skin and alopecia are in DDS Stage of the clinical study. The technology is based on HAPLN1, a protein that can reverse tissue degeneration by strengthening the extracellular matrix.
- Jul 2019Series A—
#6
Public · Seoul, Seoul · founded 2000 · 43 employees—raised▾
Established a research institute in Boston in 2000, Anterogen began commercializing products using adipose-derived stem cells for the first time in Korea.In January 2012, we obtained a market authorization of Cupistem® injection as an adipose-derived stem cell therapy product for the first time in the world.Anterogen, an emerging global leader in the field of cell therapy products, has developed Adipocell® (for the treatment of depressed scar), Queencell® (for the regeneration of subcutaneous adipose tissue) and Cupistem® injection (for the treatment of Crohn's fistula) with accumulated experiences and R&D technology in stem cell therapy
- Jan 2019Post IPO—
#7
Series A · Chuncheon si, Gangwon Province · founded 2008 · 7 employees—raised▾
Bioceltran is a private Korea based company developing various cosmetics and pharmaceutical products using its protein transduction (PTD) technology. PTD conjugated molecules show good permeability and absorb readily into the layers of the human skin in a way that the company claims is superior to liposomal formulations. It offers a range of protein (growth factors) and peptide based products for skin renewal and regeneration. PTD based cosmetic products and recombinant proteins under the trade mark SP Technology are listed in the International Cosmetic Ingredient Dictionary; and currently sold in many countries under various brands. Bioceltran claims to be offering a total solution for skin care by integrating their proprietary optical and protein chip technology with SP Technology. In Oct 2014, Quest PharmaTech (one of the shareholders in the company) agreed to license its photodynamic therapy (PDT) technology to Bioceltran in return for up-front license fees, milestone payments and royalties on future product sales.
- Oct 2014Series A—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Dermatology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.